Ad is loading...
MPEMX
Price
$7.72
Change
-$0.03 (-0.39%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

MPEMX vs RNWFX

Header iconMPEMX vs RNWFX Comparison
Open Charts MPEMX vs RNWFXBanner chart's image
Mondrian Emerging Markets Value Equity
Price$7.72
Change-$0.03 (-0.39%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
MPEMX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MPEMX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MPEMX is a Buy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. MPEMX (20M). MPEMX pays higher dividends than RNWFX: MPEMX (2.95) vs RNWFX (1.51). MPEMX was incepted earlier than RNWFX: MPEMX (17 years) vs RNWFX (23 years). MPEMX (32.00) and RNWFX (32.00) have comparable annual turnover. RNWFX has a lower initial minimum investment than MPEMX: RNWFX (250) vs MPEMX (50000). MPEMX (11.59) and RNWFX (11.54) have marching annual gain over last year. RNWFX (17.17) and MPEMX (16.64) have equivalent 5 years return.
MPEMXRNWFXMPEMX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence17 years23 years-
Gain YTD5.4647.09977%
Front LoadN/AN/A-
Min. Initial Investment5000025020,000%
Min. Initial Investment IRAN/AN/A-
Net Assets20M60.9B0%
Annual Yield % from dividends2.951.51196%
Returns for 1 year11.5911.54100%
Returns for 3 years-4.29-14.5529%
Returns for 5 years16.6417.1797%
Returns for 10 years11.8741.0029%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics